Medical

Aerie Pharmaceuticals

$15.90
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.89 (+5.91%) Today
-$0.06 (-0.38%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell AERI and other stocks, options, and ETFs commission-free!

About AERI

Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC. The listed name for AERI is Aerie Pharmaceuticals, Inc. Common Stock.

CEO
Vicente J. Anido
Employees
380
Headquarters
Durham, North Carolina
Founded
2005
Market Cap
747.16M
Price-Earnings Ratio
Dividend Yield
Average Volume
602.83K
High Today
$16.05
Low Today
$15.08
Open Price
$15.08
Volume
1.15M
52 Week High
$23.04
52 Week Low
$9.01

Collections

AERI Earnings

-$1.09
-$0.73
-$0.36
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Feb 18, After Hours

You May Also Like

AMOV
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure